推荐产品
等級
pharmaceutical primary standard
API 家族
meloxicam
製造商／商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
InChI
1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+
InChI 密鑰
DWMREKMVXIFPFM-ACCUITESSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
本产品按照发行药典的发行和规定提供。支持本产品的所有信息，包括安全数据表和任何产品信息传单，都是在发行药典的授权下开发和发布的。如需进一步信息和支持，请访问现行药典网站。
應用
Meloxicam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Meloxicam Oral Suspension
- Meloxicam Tablets
分析報告
这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。
其他說明
可能适用相应的销售限制。
相關產品
产品编号
说明
价格
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 3 Oral
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
R Andrew Moore et al.
The Cochrane database of systematic reviews, (4)(4), CD007552-CD007552 (2009-10-13)
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) used mainly in treating pain associated with arthritis. The usual oral dose for osteoarthritis is 15 mg daily, but lower doses of 7.5 mg are advised in older patients. This review sought to
[Meloxicam: intramuscular administration in rheumatology].
E S Tsvetkova
Terapevticheskii arkhiv, 75(8), 96-97 (2003-10-03)
Roy Fleischmann et al.
Expert opinion on pharmacotherapy, 3(10), 1501-1512 (2002-10-22)
Meloxicam (Mobic trade mark, Boehringer Ingelheim) is a relatively new oral non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of osteoarthritis in the US. It has also been evaluated for the treatment of rheumatoid arthritis, ankylosing spondylitis and acute 'rheumatic'
Keiko Ogino et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 120(6), 391-397 (2003-01-17)
Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a potent
Shunsuke Hamada et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 35(5), 4561-4566 (2014-01-07)
This study aimed to determine the prevalence of β-catenin nuclear positivity as a prognostic factor in patients with desmoid tumors (DTs) treated with meloxicam, a cyclooxygenase-2 (COX-2) selective inhibitor. Between 2003 and 2012, consecutive 31 patients with extraabdominal, sporadic DTs
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门